Drug Profile
L-citrulline intravenous - Asklepion Pharmaceuticals/Vanderbilt-University
Alternative Names: L-citrulline; TurnobiLatest Information Update: 03 Aug 2022
Price :
$50
*
At a glance
- Originator Vanderbilt University
- Developer Asklepion Pharmaceuticals; Vanderbilt University
- Class Amino acids; Diamino amino acids; Small molecules
- Mechanism of Action Amino acid replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Acute lung injury
- Phase II SARS-CoV-2 acute respiratory disease
- Phase I/II Vaso-occlusive crisis
Most Recent Events
- 29 Jun 2022 Asklepion Pharmaceuticals initiates a phase III trial for Acute lung injury (Prevention, In infants, In children, In adolescents) in June 2022 (IV) (NCT05253209)
- 23 Feb 2022 Asklepion Pharmaceuticals plans a phase III trial for Acute lung injury (Prevention, In infants, In children, In adolescents) in April 2022 (IV) (NCT05253209)
- 03 Feb 2022 Asklepion Pharmaceuticals completes a phase II trial in SARS-COV-2 acute respiratory disease in USA (IV) (NCT04570384)